Bio-Rad LaboratoriesBIO.B 71 OCF Yield % is 6.74 as of Jun. 25, 2026, which is 93% above its 10-year median of 3.50. GuruFocus rates BIO.B with a GF Score™ of 71/100 and a GF Value™ of $317.48 (Fairly Valued). The stock has 4 warning signs investors should review. Among 852 Medical Devices & Instruments companies, Bio-Rad Laboratories ranks better than 74.88% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Bio-Rad Laboratories OCF Yield % Related Terms
Bio-Rad Laboratories OCF Yield % Historical Data
* Premium members only.
The historical data trend for Bio-Rad Laboratories's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Bio-Rad Laboratories's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio-Rad Laboratories OCF Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bio-Rad Laboratories's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Bio-Rad Laboratories's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bio-Rad Laboratories (BIO.B) has a OCF Yield % of 6.74 as of Jun. 25, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Bio-Rad Laboratories and its competitors. This is 93% above median its historical median of 3.50. Over the past decade, Bio-Rad Laboratories' OCF Yield % has ranged from 1.26 to 8.40. According to the industry distribution chart, Bio-Rad Laboratories ranks #214 out of 852 companies in the Medical Devices & Instruments industry, placing it in the top 25.1%.
Is Bio-Rad Laboratories' OCF Yield % too high?
Bio-Rad Laboratories' current OCF Yield % of 6.74 is 93% above median its 10-year median of 3.50. Over the past 10 years, this metric has ranged from a low of 1.26 to a high of 8.40. The Medical Devices & Instruments industry median OCF Yield % is 1.76. Bio-Rad Laboratories' value of 6.74 is 283% above this industry median. Based on the distribution chart, Bio-Rad Laboratories ranks #214 out of 852 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Bio-Rad Laboratories has a GF Score™ of 71/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bio-Rad Laboratories' OCF Yield % compare to BRKR and MASI?
According to the Medical Devices & Instruments industry distribution chart, Bio-Rad Laboratories ranks #214 out of 852 companies for OCF Yield %. This puts Bio-Rad Laboratories in the upper half of its industry. The industry median OCF Yield % is 1.76. Bio-Rad Laboratories' value of 6.74 is 283% above this benchmark. Historically, Bio-Rad Laboratories' own OCF Yield % has ranged from 1.26 to 8.40 over the past decade. While the company's 10-year median is 3.50 vs. the industry median of 1.76, Bio-Rad Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Medical Devices & Instruments company?
The median OCF Yield % among Medical Devices & Instruments companies is 1.76, based on 852 companies in the industry. Companies in the top quartile (top 25%) have a OCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bio-Rad Laboratories's current OCF Yield % of 6.74 is 283% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Bio-Rad Laboratories and its competitors. For the Medical Devices & Instruments industry, the median OCF Yield % is 1.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bio-Rad Laboratories's current OCF Yield % is 6.74, which is 93% above median its own 10-year median of 3.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Rad Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Bio-Rad Laboratories (BIO.B) is currently considered Fairly Valued. The stock's GF Value™ is $317.48, compared to a current price of $296.49 — trading 6.6% below its estimated fair value. The current OCF Yield % is 6.74, which is 93% above median its 10-year median of 3.50 and 283% above the Medical Devices & Instruments industry median of 1.76. Bio-Rad Laboratories' overall GF Score™ is 71/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Bio-Rad Laboratories (BIO.B), the current OCF Yield % is 6.74 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bio-Rad Laboratories (BIO.B) Overvalued in 2026?
Based on GuruFocus' analysis, Bio-Rad Laboratories stock appears to be undervalued.
The current stock price of $296.49 is trading 6.6% below its estimated GF Value™ of $317.48.
GuruFocus considers Bio-Rad Laboratories to be Fairly Valued.
Key valuation signals for BIO.B:
OCF Yield %: 6.74 (93% above median its 10-year median of 3.50)
GF Value™: $317.48 vs. price of $296.49 (6.6% below fair value)
Industry Position: 283% above the Medical Devices & Instruments median (#214 of 852)
No single metric tells the full story. See the BIO.B stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
71GF Score
Get the complete analysis for BIO.B
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BIO.B has been successfully added to your 
